Together, these data highlight the complexity of GFL-RET signaling and the potential benefits and challenges of new therapeutic strategies for targeting this pathway that are rapidly transitioning to the clinic, to change cancer management and improve patient outcomes. The gene discussed is RET; the disease is cancer.